Why the study?
Despite advances in oral anticoagulation for stroke prevention, a significant residual vascular risk remains associated with silent AF, bleeding, premature sudden death, and heart failure.
This review highlights the residual vascular risk in atrial fibrillation despite advances in oral anticoagulation and calls for optimized management strategies in Portugal.
No takes yet. Share an insight, caveat, or question.
Residual AF risks persist despite NOACs; leaves open targeted strategies for silent AF, bleeding, and HF.
Ferreira et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: